AR106756A1 - Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk - Google Patents
Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrkInfo
- Publication number
- AR106756A1 AR106756A1 ARP160103546A ARP160103546A AR106756A1 AR 106756 A1 AR106756 A1 AR 106756A1 AR P160103546 A ARP160103546 A AR P160103546A AR P160103546 A ARP160103546 A AR P160103546A AR 106756 A1 AR106756 A1 AR 106756A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- monocyclic
- hydroxyalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: el anillo A se selecciona entre arilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, cicloalquilo y heterociclilo; cada RA se selecciona en forma independiente entre arilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, cicloalquilo monocíclico o bicíclico, heterociclilo monocíclico o bicíclico, C₁₋₆ alquilo, C₁₋₆ alcoxilo, halo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, -N(R¹)(R¹), nitro, ciano, -C(O)R¹, -OC(O)R¹, -C(O)OR¹, -SR¹, -S(O)₂R¹, -S(O)₂-N(R²)(R²), -(C₁₋₆ alquilen)-S(O)₂-N(R²)(R²), -C(O)-N(R²)(R²), -N(R²)(R²)-C(O)R¹, -(C₁₋₆ alquilen)-N(R²)-C(O)R¹, -NR²S(O)₂R¹, -P(O)(R¹)(R¹), y -OR¹; donde cada uno de arilo, heteroarilo, cicloalquilo, heterociclilo, alquilo, alcoxilo, haloalquilo, hidroxialquilo, heteroalquilo está sustituido en forma independiente con 0 - 5 instancias de Rᵃ; cada RB se selecciona en forma independiente entre C₁₋₆ alquilo, C₁₋₆ alcoxilo, halo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, -N(R¹)(R¹), nitro, ciano, y -OR¹; cada R¹ se selecciona en forma independiente entre hidrógeno, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, y heterociclilalquilo, donde cada uno de C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, y heterociclilalquilo está sustituido en forma independiente con 0 - 5 instancias de Rᵇ; cada R² se selecciona en forma independiente entre hidrógeno, C₁₋₆ alquilo, C₁₋₆ heteroalquilo; o 2 R² junto con el nitrógeno al cual están unidos forman un anillo heterociclilo sustituido con 0 - 5 instancias de Rᵇ; cada Rᵃ y Rᵇ se selecciona en forma independiente entre halo, ciano, hidroxilo, C₁₋₆ alquilo, C₁₋₆ alcoxilo, C₁₋₆ haloalcoxilo, -N(R)(R), -C(O)-N(R)(R), -N(R)(R)-C(O)R, y -(C₁₋₆ alquilen)-N(R)-C(O)R; cada R y R se selecciona en forma independiente entre hidrógeno y C₁₋₆ alquilo o C₁₋₆ hidroxialquilo; m es 0, 1, 2, 3, 4 ó 5; y n es 0, 1 ó 2; con la condición de que el compuesto no es (R)-5-(2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-carbonitrilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257476P | 2015-11-19 | 2015-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106756A1 true AR106756A1 (es) | 2018-02-14 |
Family
ID=57517997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103546A AR106756A1 (es) | 2015-11-19 | 2016-11-18 | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10370379B2 (es) |
| EP (1) | EP3377497A1 (es) |
| JP (1) | JP2019500328A (es) |
| KR (1) | KR20180081790A (es) |
| CN (1) | CN108431008A (es) |
| AR (1) | AR106756A1 (es) |
| AU (1) | AU2016355196A1 (es) |
| BR (1) | BR112018010024A8 (es) |
| CA (1) | CA3005741A1 (es) |
| HK (1) | HK1259453A1 (es) |
| IL (1) | IL259164A (es) |
| MX (1) | MX2018006195A (es) |
| PH (1) | PH12018501065A1 (es) |
| RU (1) | RU2018122089A (es) |
| SG (2) | SG11201803920TA (es) |
| TW (1) | TWI733713B (es) |
| WO (1) | WO2017087778A1 (es) |
| ZA (1) | ZA201803530B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EP3409674B1 (en) | 2013-10-17 | 2022-04-06 | Blueprint Medicines Corporation | Process for preparing compositions useful for treating disorders related to kit |
| JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| RU2744974C2 (ru) | 2015-08-26 | 2021-03-17 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
| TWI787018B (zh) | 2015-11-02 | 2022-12-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| AU2016355196A1 (en) | 2015-11-19 | 2018-06-21 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| ES2957233T3 (es) | 2016-04-15 | 2024-01-15 | Blueprint Medicines Corp | Inhibidores de quinasa tipo receptor de activina |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
| LT3773589T (lt) | 2018-04-03 | 2024-02-12 | Blueprint Medicines Corporation | Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui |
| JP7385658B2 (ja) | 2018-10-30 | 2023-11-22 | クロノス バイオ インコーポレイテッド | Ｃｄｋ９活性を調節するための化合物、組成物、および方法 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TW202104232A (zh) | 2019-04-12 | 2021-02-01 | 美商藍印藥品公司 | (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业（成都）有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5251911A (en) | 1992-12-09 | 1993-10-12 | Blake Carlton E | Safety construction for passenger vehicle |
| WO1998014450A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| ES2346204T3 (es) * | 2002-09-04 | 2010-10-13 | Schering Corporation | Pirazolopirimidinas adecuadas para el tratamiento de enfermedades cancerosas. |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| BRPI0509576A (pt) | 2004-04-02 | 2007-05-29 | Osi Pharm Inc | composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| DK3106463T6 (da) | 2008-10-22 | 2020-02-24 | Array Biopharma Inc | Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CA2761074A1 (en) | 2010-05-05 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| US8637516B2 (en) * | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (zh) * | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| WO2014036387A2 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of Colorado | Methods for diagnosis and treatment of cancer |
| EA201590693A1 (ru) * | 2012-10-05 | 2015-08-31 | Ригель Фармасьютикалс, Инк. | Ингибиторы gdf-8 |
| WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| CA2899662A1 (en) | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| RU2672910C9 (ru) * | 2013-02-21 | 2019-06-04 | Калитор Сайенсез, ЛЛС | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| EP3409674B1 (en) | 2013-10-17 | 2022-04-06 | Blueprint Medicines Corporation | Process for preparing compositions useful for treating disorders related to kit |
| JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
| WO2015108328A1 (ko) * | 2014-01-14 | 2015-07-23 | 주식회사 엘지생명과학 | 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도 |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US10233170B2 (en) * | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| RU2708674C2 (ru) | 2014-12-15 | 2019-12-11 | СиЭмДжи ФАРМАСЬЮТИКАЛ КО., ЛТД. | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| US9981944B2 (en) | 2015-02-20 | 2018-05-29 | Rigel Pharmaceuticals, Inc | GDF-8 inhibitors |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| RU2744974C2 (ru) | 2015-08-26 | 2021-03-17 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
| TWI787018B (zh) | 2015-11-02 | 2022-12-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| AU2016355196A1 (en) | 2015-11-19 | 2018-06-21 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| ES2957233T3 (es) | 2016-04-15 | 2024-01-15 | Blueprint Medicines Corp | Inhibidores de quinasa tipo receptor de activina |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-11-18 AU AU2016355196A patent/AU2016355196A1/en not_active Abandoned
- 2016-11-18 US US15/355,425 patent/US10370379B2/en active Active
- 2016-11-18 EP EP16808868.0A patent/EP3377497A1/en not_active Withdrawn
- 2016-11-18 JP JP2018525688A patent/JP2019500328A/ja not_active Ceased
- 2016-11-18 BR BR112018010024A patent/BR112018010024A8/pt not_active IP Right Cessation
- 2016-11-18 RU RU2018122089A patent/RU2018122089A/ru not_active Application Discontinuation
- 2016-11-18 WO PCT/US2016/062731 patent/WO2017087778A1/en active Application Filing
- 2016-11-18 CN CN201680077637.8A patent/CN108431008A/zh active Pending
- 2016-11-18 CA CA3005741A patent/CA3005741A1/en not_active Abandoned
- 2016-11-18 MX MX2018006195A patent/MX2018006195A/es unknown
- 2016-11-18 SG SG11201803920TA patent/SG11201803920TA/en unknown
- 2016-11-18 KR KR1020187016321A patent/KR20180081790A/ko unknown
- 2016-11-18 AR ARP160103546A patent/AR106756A1/es unknown
- 2016-11-18 TW TW105137936A patent/TWI733713B/zh not_active IP Right Cessation
- 2016-11-18 SG SG10201912607SA patent/SG10201912607SA/en unknown
-
2018
- 2018-05-06 IL IL259164A patent/IL259164A/en unknown
- 2018-05-17 PH PH12018501065A patent/PH12018501065A1/en unknown
- 2018-05-28 ZA ZA2018/03530A patent/ZA201803530B/en unknown
-
2019
- 2019-02-01 HK HK19101858.8A patent/HK1259453A1/zh unknown
- 2019-07-31 US US16/527,773 patent/US11059827B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180081790A (ko) | 2018-07-17 |
| WO2017087778A1 (en) | 2017-05-26 |
| ZA201803530B (en) | 2021-08-25 |
| US10370379B2 (en) | 2019-08-06 |
| BR112018010024A8 (pt) | 2019-02-26 |
| BR112018010024A2 (pt) | 2018-11-21 |
| SG10201912607SA (en) | 2020-02-27 |
| RU2018122089A (ru) | 2019-12-25 |
| US20170145018A1 (en) | 2017-05-25 |
| EP3377497A1 (en) | 2018-09-26 |
| IL259164A (en) | 2018-06-28 |
| AU2016355196A1 (en) | 2018-06-21 |
| CN108431008A (zh) | 2018-08-21 |
| US20190382410A1 (en) | 2019-12-19 |
| US11059827B2 (en) | 2021-07-13 |
| PH12018501065A1 (en) | 2019-01-28 |
| JP2019500328A (ja) | 2019-01-10 |
| TW201720826A (zh) | 2017-06-16 |
| HK1259453A1 (zh) | 2019-11-29 |
| MX2018006195A (es) | 2018-09-05 |
| TWI733713B (zh) | 2021-07-21 |
| RU2018122089A3 (es) | 2019-12-30 |
| SG11201803920TA (en) | 2018-06-28 |
| CA3005741A1 (en) | 2017-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106756A1 (es) | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| MX2019005306A (es) | Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| EA201892436A1 (ru) | Пиримидиновые соединения в качестве ингибиторов jak киназы | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| MX2016002367A (es) | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. | |
| MX370906B (es) | Inhibidores de serina/treonina cinasa. | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR089550A1 (es) | Compuestos quimicos | |
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
| EA201790745A1 (ru) | Трициклические соединения | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR104262A1 (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas |